Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

David Cella, Jan McKendrick*, Amber Kudlac, Antonio Palumbo, Abderrahim Oukessou, Ravi Vij, Teresa Zyczynski, Catherine Davis

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications—one of the most frequent and debilitating being bone pain. In the ELOQUENT-2 study (NCT01239797), which evaluated the addition of elotuzumab to lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone, pain and HRQoL were assessed in patients with relapsed/refractory disease using the Brief Pain Inventory–Short Form (BPI-SF) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 module (QLQ-C30) and myeloma-specific module (QLQ-MY20). Mean baseline pain scores were low and remained so throughout treatment with both regimens; mean HRQoL scores did not change substantially from baseline. A significantly higher proportion of patients with objective response than without had clinically meaningful improvements in worst pain over two consecutive treatment cycles (29 versus 12%; p < 0.001). Patients with very good partial response (VGPR) or better reported reduced scores for pain severity and worst pain; those with progressive disease reported increased scores for these domains and pain interference. These findings show that previously reported improvements in progression-free survival and response rate with elotuzumab are achieved without detriment to HRQoL, which is maintained over time.

Original languageEnglish (US)
Pages (from-to)2455-2463
Number of pages9
JournalAnnals of Hematology
Volume97
Issue number12
DOIs
StatePublished - Dec 1 2018

Keywords

  • Health-related quality of life
  • Multiple myeloma
  • Pain
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study'. Together they form a unique fingerprint.

  • Cite this